PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Publication|Videos|May 30, 2024
Recent Pharma Trends, EU Annex 1, and More with Syntegon
Author(s)Syntegon Pharma Technology
At a recent INTERPHEX conference, Laura Moody (Director of Product Management, Pharma North America, Syntegon) shared some insights into current trends in the pharmaceutical industry, including the EU Annex 1.
Between bigger commitments to sustainability, updated regulatory requirements, and increasingly innovative equipment, the pharmaceutical industry is undergoing a great deal of change. To learn more, Pharmaceutical Technology spoke with Laura Moody, Director of Product Management for Pharma North America at Syntegon. Watch this video to learn more about:
- The current landscape of the pharmaceutical industry, including current trends;
- How the EU Annex 1 affects pharmaceutical companies;
- How Syntegon supports pharmaceutical companies in drug making processes.
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Trending on Pharmaceutical Technology
1
FDA's IND Pilot Puts CMC Review First
2
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
3
Lessons For AI Governance in Quality Systems
4
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
5